Distribution Chemotherapy Response Modulating Genetic Polymorphisms in Armenian Population

Primary chemotherapy drug resistance is a one of the major issues of medical hematology-oncology affecting about 20% of all patients. In Armenia, clinical data suggest that the rate of primary resistance depends on the disease and treatment type and varies in the range of 10-30%. One of the mechanisms of resistance is a drug inactivation mediated by metabolizing enzymes and it has been known that the variability of those genes contributes to the response to drugs and treatment efficacy. In Armenia a number of drugs are used for treatment acute and chronic hematology-oncological diseases, such as doxorubicin and vincristine (leukemia or lymphoma), rituximab (lymphoma), cladribine (hairy cell leukemia), interferon alfa-2a (chronic myeloid leukemia) and asparaginase (acute lymphoblastic leukemia).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research